Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

[Research Progress of Post-Transplant Cyclophosphamide Combined with Antithymocyte Globulin in Preventing GVHD after Hematopoietic Stem Cell Transplantation --Review].

Author information

Affiliations

  • 1. Health Science Center, Ningbo University, Ningbo 315211, Zhejiang Province, China.
      Authors
    • Wu MJ 1
    (1 author)
  • 2. Department of Hematology, The Affiliated Hospital of Health Science Center, Ningbo University, Ningbo 315100, Zhejiang Province, China E-mail
      Authors
    • Ye PP 2
    (1 author)

Zhongguo shi yan xue ye xue za zhi, 01 Dec 2023, 31(6):1899-1904Language:chi
https://doi.org/10.19746/j.cnki.issn.1009-2137.2023.06.047 PMID: 38071080 

Abstract 

Graft-versus-host disease (GVHD) is one of the major complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT), which seriously affects the prognosis of patients. At present, a new regimen of post-transplantation cyclophosphamide (PTCy) combined with antithymocyte globulin (ATG) has been used to prevent GVHD, indicating that PTCy combined with ATG may have a good effect on the prevention of GVHD in different types of transplantation. However, the mechanism of this regimen, its effect on immune reconstitution and viral reactivation still needs to be further studied. Therefore, this article briefly reviews the research progress of PTCy combined with ATG in preventing GVHD after HSCT.

Full text links 

Read article at publisher's site: https://doi.org/10.19746/j.cnki.issn.1009-2137.2023.06.047

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.